IgG4-Related Disease Market Project to Grow with a CAGR of 34.6% Through 2034, DelveInsight Finds

The IgG4-Related Disease market was valued at approximately USD 180 million in 2025 and is projected to grow at a robust CAGR of 34.6% during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the IgG4-RD landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The IgG4-RD market is increasingly guided by breakthrough B-cell targeted therapies. UPLIZNA (inebilizumab-cdon) by Amgen represents a highly transformative breakthrough, emerging as the first and only FDA-approved treatment for IgG4-RD following its historic approval in April 2025. UPLIZNA's approval validates IgG4-RD as a distinct clinical entity requiring specialized therapeutic intervention, marking a fundamental paradigm shift away from traditional corticosteroid-dependent management toward precision B-cell targeting approaches.

To know in detail about the IgG4-Related Disease market outlook, drug uptake, treatment scenario and epidemiology trends, visit IgG4-Related Disease Market Forecast

IgG4-Related Disease Overview

Immunoglobulin G4-Related Disease (IgG4-RD) is a chronic, immune-mediated fibroinflammatory condition characterized by infiltration of IgG4-positive plasma cells into various organ systems, causing tumefactive lesions, fibrosis, and permanent organ damage. IgG4-RD is a systemic fibroinflammatory disorder that can impact nearly any organ, with pancreas, bile duct, salivary and lacrimal glands, orbits, lungs, and retroperitoneum being the most frequently affected sites. This rare autoimmune condition is marked by elevated serum IgG4 levels and the presence of IgG4-positive plasma cells in affected tissues, often leading to multi-organ involvement and complex clinical presentations. Only identified as a unique disease entity in 2003, IgG4-RD has rapidly emerged as an important area requiring specialized clinical expertise and targeted therapeutic intervention.

IgG4-RD often presents with particular preference for pancreatic involvement, frequently manifesting as Type 1 IgG4-Related Autoimmune Pancreatitis (AIP). The multi-organ nature of IgG4-RD requires comprehensive disease monitoring and specialized expertise often unavailable in routine clinical settings, contributing to significant diagnostic delays and substantial treatment gaps in both developed and emerging markets.

IgG4-Related Disease Epidemiology

The epidemiological landscape of IgG4-RD reveals substantial disease burden with increasing recognition across major healthcare systems. According to DelveInsight's analysis, the 7MM market encompassed approximately 150K diagnosed prevalent cases in 2024, with the United States accounting for 38% of the cases.

Furthermore, the IgG4-RD epidemiology demonstrates pronounced male predominance with a male-to-female gender ratio of approximately 69% to 31%, affecting primarily middle-aged patients in their forties to sixties. In 2024, gender-specific diagnosed prevalent cases accounted for approximately 40K cases in males and 18K cases in females in the United States. Age-specific analysis revealed a higher percentage of diagnosed prevalent cases observed in age groups 65 years and above, particularly in the age group 75 years and older.

IgG4-Related Disease Epidemiology Segmentation 

• Total diagnosed prevalent cases of IgG4-RD
• Gender-specific diagnosed prevalent cases of IgG4-RD
• Age-specific diagnosed prevalent cases of IgG4-RD

Download the report to understand which factors are driving IgG4-Related Disease epidemiology trends @ IgG4-Related Disease Epidemiology Forecast

IgG4-Related Disease Market Dynamics and Key Trends

• The IgG4-RD market is increasingly guided by multiple convergent factors, including enhanced disease recognition among healthcare providers, improved diagnostic capabilities, and the growing elderly population most susceptible to IgG4-RD manifestations. Advanced diagnostic approaches incorporating immunohistochemical staining, serum IgG4 level measurement, and sophisticated imaging modalities including PET scans enable earlier disease recognition and intervention.
• Market growth is largely fueled by rising awareness and advancements in diagnostic capabilities, especially with the increased availability of immunohistochemical and serological testing for IgG4-RD, enabling earlier and more accurate diagnoses across clinical settings. Growing healthcare expenditure allocation toward rare disease management and increased focus on managing rare autoimmune conditions are driving demand for targeted therapeutic solutions. The growing prevalence of autoimmune and inflammatory disorders, coupled with rising awareness among healthcare providers and patients, significantly drives demand for targeted therapeutic options, particularly innovative biologics addressing underlying disease mechanisms rather than reliance on conventional corticosteroids.
  
• Key trends shaping the IgG4-RD market include the rising adoption of B-cell targeted therapies, particularly CD19+ B-cell depletion approaches, expanding implementation of personalized medicine strategies, and enhanced collaboration between rheumatology, pathology, and radiology departments. The convenience of non-invasive imaging tools, targeted biologics, and improved disease classification systems are key factors propelling the adoption of comprehensive care strategies in both hospital and outpatient settings.
  
• The IgG4-RD market faces challenges including disease rarity and complexity creating physician awareness obstacles, particularly in non-specialized practice settings. Lack of standardized diagnostic criteria complicates consistent disease identification and treatment monitoring across healthcare systems. However, supportive regulatory pathways evidenced by breakthrough therapy designations, orphan drug designations, and fast track designations across the pipeline are accelerating therapeutic development and clinical advancement.

Latest FDA-Approved Therapies and Companies

The landscape of IgG4-RD therapeutics underwent transformative change with Amgen's groundbreaking FDA approval of UPLIZNA (inebilizumab-cdon) in April 2025, representing the first and only FDA-approved treatment for IgG4-RD. UPLIZNA represents a breakthrough CD19+ B-cell targeted therapy specifically designed to address the pathogenic B-cell cascade underlying IgG4-RD pathophysiology.

Clinical trial data from the landmark MITIGATE trial demonstrated UPLIZNA's substantial efficacy in reducing disease flare risk. An 87% reduction in the risk of IgG4-RD flare was observed compared to placebo (Hazard Ratio 0.13, p<0.001) during the 52-week placebo-controlled period, with 10.3% (7 of 68) of participants receiving UPLIZNA experiencing a flare compared to 59.7% (40 of 67) of participants receiving placebo. UPLIZNA demonstrated significant clinical benefits in achieving disease remission while reducing reliance on long-term glucocorticoid therapy, fundamentally advancing treatment paradigms beyond steroid-based management and reducing long-term toxicity risks associated with chronic glucocorticoid exposure.

IgG4-Related Disease Pipeline and Emerging Therapies

The IgG4-RD pipeline encompasses several promising therapeutic candidates addressing unmet medical needs and offering differentiated mechanisms of action. Obexelimab (XmAb5871), a fully human monoclonal antibody targeting the transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI), represents an emerging therapeutic option currently in late-stage development through a strategic partnership between Zenas BioPharma and Bristol Myers Squibb. Targeted enrollment is complete in the INDIGO trial, a global Phase 3 registration-directed, double-blind, placebo-controlled trial to evaluate the safety and efficacy of obexelimab in patients with active IgG4-RD, with approximately 190 patients enrolled in the randomized control period across approximately 100 sites in 20 countries.

Rilzabrutinib, a selective non-covalent Bruton tyrosine kinase (BTK) inhibitor being developed by Sanofi following its acquisition of Principia Biopharma, represents another differentiated approach to IgG4-RD management. Rilzabrutinib offers oral administration routes and alternative mechanisms targeting intracellular signaling cascades within B-cell populations, with phase 2 data showing 70% of patients remaining flare-free at 52 weeks. BTK inhibitors interfere with B-cell activation and differentiation, providing complementary mechanisms to CD19+ B-cell depletion approaches.

Rituximab, a chimeric monoclonal antibody targeting the CD20 antigen on B cells, continues to serve important clinical roles despite off-label utilization in IgG4-RD management. Rituximab demonstrates high efficacy in depleting circulating CD20+ B cells and indirectly reducing disease-associated CD20−CD27+CD38++ plasmablasts, making it uniquely suited to interrupt the pathogenic B-cell cascade characterizing IgG4-RD.

To know more about IgG4-Related Disease companies working in the treatment market, visit @ IgG4-Related Disease Clinical Trials and Therapeutic Assessment

IgG4-Related Disease Competitive Landscape

The IgG4-RD competitive landscape encompasses leading pharmaceutical companies positioned across diverse therapeutic development stages. Key IgG4-RD companies include Amgen (UPLIZNA), Zenas BioPharma (obexelimab in partnership with Bristol Myers Squibb), Sanofi (rilzabrutinib), and other pharmaceutical organizations pursuing distinct therapeutic strategies targeting B-cell populations, plasmablasts, T-cell pathways, and immunoglobulin production mechanisms.

Amgen's market leadership position following UPLIZNA's historic FDA approval in April 2025 positions the company prominently within the IgG4-RD therapeutic space. Amgen demonstrated UPLIZNA's commercial potential through its existing franchise in NMOSD, generating USD 379 million in annual revenue during 2024, providing substantial commercial infrastructure supporting IgG4-RD market penetration. The competitive landscape will evolve significantly as obexelimab and rilzabrutinib advance through late-stage development, offering differentiated mechanisms and administration routes. Healthcare executives should recognize this rare autoimmune market's substantial commercial potential while anticipating competitive dynamics that will ultimately benefit patients through expanded treatment options and improved clinical outcomes.

IgG4-Related Disease Market Unmet Medical Needs and Opportunities

Substantial unmet medical needs persist despite recent therapeutic advances. Currently, the curative treatments are limited for IgG4-RD due to incomplete understanding of disease pathophysiology and complex multi-organ involvement patterns. Conventional glucocorticoid-based management carries significant long-term toxicity risks, while immunosuppressive alternatives lack definitive efficacy evidence and carry substantial treatment-related morbidity. Approximately 20-30% of diagnosed patients receive no systemic therapy, instead opting for surgical interventions or watchful waiting strategies.

The multi-organ nature of IgG4-RD creates complex diagnostic and treatment challenges requiring specialized expertise unavailable in many clinical settings. Enhanced diagnostic tools incorporating advanced biomarker panels, imaging modalities, and tissue-based assessments enable earlier disease recognition and intervention. Growing healthcare expenditure allocation toward rare disease management supports premium pricing acceptance for innovative biologics addressing substantial unmet needs. The IgG4-Related Disease market stands at an unprecedented inflection point, driven by the first FDA-approved therapy UPLIZNA and robust pipeline development from leading pharmaceutical companies.

Conclusion

DelveInsight's comprehensive market research demonstrates that the IgG4-Related Disease market represents one of the most promising rare autoimmune therapeutic areas, positioned for remarkable growth through 2034. With the market projected to grow at a remarkable CAGR of 34.6%, regulatory support accelerating therapeutic development, and research uncovering promising new treatments, leading companies are working tirelessly to address this rare but serious condition affecting multiple organ systems. The FDA approval of UPLIZNA by Amgen validates IgG4-RD as a distinct clinical entity deserving specialized therapeutic intervention, fundamentally reshaping treatment paradigms and expanding opportunities for patients previously limited to corticosteroid-dependent management strategies. Healthcare stakeholders should maintain strategic focus on this evolving therapeutic landscape to capitalize on substantial commercial opportunities while advancing patient care and clinical outcomes.

For detailed information about the IgG4-Related Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, please download the IgG4-Related Disease Market Report

Some of the Key Facts of the IgG4-Related Disease Market Report:

• Key IgG4-Related Disease Companies: Amgen, Zenas BioPharma, Bristol Myers Squibb, Sanofi, and others

• Key IgG4-Related Disease Therapies: UPLIZNA (inebilizumab-cdon), obexelimab (XmAb5871), rilzabrutinib, rituximab, and others

• The IgG4-Related Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage IgG4-Related Disease pipeline products will significantly revolutionize the IgG4-Related Disease market dynamics.

Recent Developments in the IgG4-RD Treatment Landscape:

• In April 2025, Amgen's UPLIZNA (inebilizumab-cdon) received FDA approval as the first and only treatment for adults with IgG4-Related Disease (IgG4-RD). This represents a significant milestone as the first-ever FDA-approved therapy for this rare, chronic immune-mediated condition. The approval is based on positive data from the Phase III MITIGATE trial.​
• In April 2025, Sanofi announced FDA's orphan drug designation for rilzabrutinib, a promising drug candidate for IgG4-RD treatment. Sanofi's Phase II trials showed efficacy in reducing disease flares, and rilzabrutinib's pipeline addition strengthened Sanofi’s immunology portfolio.
• New data from Sanofi's Phase 2 rilzabrutinib study was highlighted in June 2025, reinforcing its potential for IgG4-RD flares reduction and glucocorticoid tapering benefits.

Scope of the IgG4-RD Market Report

• Study Period: 2025–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key IgG4-RD Companies
• Key IgG4-RD Therapies
• IgG4-RD Therapeutic Assessment: IgG4-RD current marketed therapies and IgG4-RD emerging therapies
• IgG4-RD Market Dynamics: IgG4-RD market drivers and IgG4-RD market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• IgG4-RD Unmet Needs, KOL's views, Analyst's views, IgG4-RD Market Access and Reimbursement